Step Considerations for Life Sciences Co. Amidst the COVID - McDermott

Action Step Considerations for Life Sciences Companies Amidst the COVID-19 Pandemic


The impact of Coronavirus (COVID-19) on life science and medical device companies has been unique. Not only have these businesses been required to set up emergency management systems practically overnight to maintain normal business operations, but the sector is expected to make significant contributions to the fight against COVID-19 across the globe.

With new challenges arising each day, as well as regulatory changes and mounting pressure on the healthcare ecosystem, we are closely tracking, digesting and advising life sciences clients on COVID-19-related issues across virtually every area impacted by this crisis. We are currently advising life sciences, healthcare and technology companies as they adapt their products and services and indeed their facilities and distribution channels to aid in the pandemic response, maintain commercial viability, implement risk mitigation strategies, and navigate highly complex regulatory hurdles and compliance obligations.